Athyrium Capital Management, LP

Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations

Athyrium advises funds with over $4 5 billion of committed capital

Basilea Announces CHF 75 Million Senior Secured Loan Agreement with Athyrium RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing uMotif Expands Leadership Team to Support Growth in US and EU Markets uMotif Announces $25 5m Investment from Fund Managed by Athyrium Capital Management Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management Puma Biotechnology Announces $10 Million Private Placement Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection Athyrium is a specialized asset management company which advises funds with over $4 5 billion in committed capital Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations

Sign up for updates and news from Athyrium Capital Management Your email will not be distributed or used for any third party purposes